3 Under-$5 TSX Stocks That Could Double in a Year

Bay Street analysts expect these three under-$5 stocks to more than double within a year. Buy them today to get high returns on your investment.

| More on:
Hand arranging wood block stacking as step stair with arrow up.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Stocks continue to rally in 2021. June is the sixth month in a row the TSX Composite Index has reached a fresh record high. Nonetheless, some tiny stocks still look undervalued. Bay Street analysts expect some of these stocks to more than double in the next 12 months. Most of these companies are still at their initial or development stage with huge future growth potential. Let’s take a closer look at three of such under-$5 Canadian stocks to buy today.

IMV stock

IMV (TSX:IMV)(NASDAQ:IMV) is a Dartmouth-based clinical-stage biopharmaceutical firm with a market cap of $195 million. The company is currently focused on making immunotherapy more effective and widely available to people facing serious diseases, including cancer. Its stock is currently trading at $2.87 per share with about 26.2% year-to-date losses. Bay Street analysts expect IMV stock to reach $7.81 per share in the next 12 months — reflecting an upside potential of 172% from its current market price.

In the first quarter of 2021, IMV’s adjusted net loss per share improved to $0.12 per share than a net loss of $0.20 per share a year ago. It was also better than analysts’ consensus estimate of $0.16 net loss per share. During the quarter, its revenue rose by 17% year over year to $83.4 thousand.

Medicenna Therapeutics stock

Medicenna Therapeutics (TSX:MDNA)(NASDAQ:MDNA) is another Canadian clinical-stage immunotherapy company focusing on the treatment of a broad range of cancers. Its stock is currently trading at $4.59 per share with a market cap of $244 million. Medicenna Therapeutics’s management plans to expand its clinical-stage pipeline in the near future. While the company is currently conducting its clinical trial in Australia and the U.K., it plans to expand the trial to the U.S. and Canada after completing the study’s dose-escalation and after getting respective regulatory approvals.

Interestingly, the stock has yielded nearly 200% positive returns in the last three years. Analysts expect Medicenna’s stock to rise to $11.54 per share in the next 12 months — reflecting an upside potential of more than 150% at the moment.

Oncolytics Biotech stock

Oncolytics Biotech (TSX:ONC)(NASDAQ:ONCY) is Calgary-headquartered biotechnology and medical research firm with a market cap of $188 million. The company is currently developing a pelareorep — an intravenously delivered immuno-oncolytic virus to treat a variety of cancers.

Its stock fell by 50% in 2020 after posting solid 145% gains in 2019. It’s currently trading with about 18% year-to-date gains. Bay Street analysts expect Oncolytics Biotech stock to reach $7.67 in the next 12 months — up 115% from its current market price of $3.56 per share. At the end of the March 2021 quarter, it had $50.4 million in cash and cash equivalents, while its Q1 research and development expenses stood at $2.8 million. Oncolytics is expected to release key data from many of the ongoing studies this year. A positive data release from any of these studies could trigger a buying spree in Oncolytics Biotech stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Jitendra Parashar has no position in any of the stocks mentioned.

More on Stocks for Beginners

Man data analyze
Stocks for Beginners

Beginners: 2 Market-Beating Stocks Just Getting Started

Brookfield Asset Management (TSX:BAM.A)(NYSE:BAM) and Constellation Software (TSX:CSU) are proven market beaters that could continue their ways.

Read more »

Stocks for Beginners

Have $10,000? Top 2 Stocks You Should Invest it in

Passive-income stocks like BCE (TSX:BCE)(NYSE:BCE) could be good opportunities in 2022.

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Stocks for Beginners

3 Blue-Chip Stocks to Buy Today and Never Let Go

Old and new investors alike will worry less about market volatility if blue-chip stocks are the backbones of their investment…

Read more »

edit Businessman using calculator next to laptop
Stocks for Beginners

Got $6,000? Here’s How You Can Power Your TFSA in August

Are you hoping to contribute to your TFSA? Power your portfolio with these three stocks!

Read more »

edit Person using calculator next to charts and graphs
Stocks for Beginners

TFSA Investors: 3 Stocks With Unbelievable Staying Power

Are you looking for stocks to add to your TFSA? Here are three stocks with unbelievable staying power!

Read more »

TFSA and coins
Stocks for Beginners

Got $6,000? 2 Cheap Stocks to Buy for Your TFSA Right Now

Here's two cheap stocks that could blow away growth estimates and set you up well in the long run.

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

3 Top TSX Stocks That Saw Bumper Q2 Earnings Growth

Some stocks are seeing epic growth even as the market braces for a recession.

Read more »

Target. Stand out from the crowd
Stocks for Beginners

3 Stocks That Are Great Long-Term Picks

Are you looking for stocks that you can hold for the long run? Here are three great long-term picks!

Read more »